Abstract. Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and has an extremely poor prognosis. Surgical resection is always inapplicable to HCC patients diagnosed at an advanced tumor stage. The mechanisms underlying HCC cell proliferation remain obscure. In the present study, SWItch/sucrose nonfermentable catalytic subunit SNF2 (SNF2H) expression was tested in HCC tissues and Wnt/β-catenin pathway activation upon overexpression of SNF2H or knockdown of SNF2H expression was investigated in cultured HCC cells. It was demonstrated that SNF2H is a vital factor for HCC growth. The SNF2H expression level is increased in HCC tissues compared with paratumoral liver tissues. SNF2H promotes HCC cell proliferation and colony formation ability in vitro. SNF2H may increase the protein level of β-catenin and enhance its nuclear accumulation in HCC cells, thereby leading to the activation of the Wnt/β-catenin signaling pathway. In conclusion, the present results indicate that SNF2H plays a vital role in HCC cell growth, suggesting that SNF2H may be a promising therapeutic target for HCC treatment.
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common tumor in men and the seventh most common tumor in women. It is the third leading cause of tumor-associated mortality worldwide (1) . HCC has an extremely poor prognosis, with a 5-year survival rate of 40-50%. Patients with HCC are usually diagnosed at an advanced tumor stage, which renders surgical resection inapplicable (2) . The molecular mechanism underlying HCC cell proliferation is not well understood, and the clarification of this mechanism may facilitate the prevention and treatment of patients with HCC.
Approximately one-half of HCC patients exhibit aberrant activation of the Wnt/β-catenin pathway, which indicates the importance of this signaling cascade in hepatocarcinogenesis (3) (4) (5) . The Wnt/β-catenin signaling pathway is comprehensively involved in cell proliferation (6) . The Wnt/β-catenin pathway is activated upon the binding of the Wnt ligands to Frizzled receptors, which is followed by cytosolic accumulation of β-catenin via interruption of destruction complex-mediated protein degradation of β-catenin. Stabilized β-catenin may translocate into the nucleus to induce the transcription of Wnt/β-catenin pathway target genes, such as cyclin D1 and cellular v-myc avian myelocytomatosis viral oncogene homolog (c-MYC) (4, 7) . The Wnt/β-catenin signaling pathway plays a vital role in hepatocarcinogenesis. Although several factors, such as activator protein 1, human zinc finger protein 191, prospero homeobox protein 1 and T-cell factor (TCF)/lymphocyte enhancer factor (LEF), have been reported to regulate β-catenin expression (8) (9) (10) (11) , the molecular mechanism of the aberrant expression of β-catenin remains unknown in HCC.
SWItch/sucrose nonfermentable (SWI/SNF) catalytic subunit SNF2 (SNF2H) is a member of the SWI/SNF chromatin remodeling family with ATPase activity (12) . SNF2H plays a vital role in gene transcription, DNA repair and DNA replication (12, 13) . SWI/SNF complexes are associated with malignant transformation (14) . Previously, several studies have reported aberrant high expression of SNF2H in breast cancer, acute leukemia, ovarian cancer and gastric cancer (15) (16) (17) . These studies suggest that SNF2H has an important role in cancer progression. However, whether SNF2H plays a vital role in HCC progression has not been investigated.
In the present study, it was demonstrated that SNF2H plays a vital role in HCC cell growth. The SNF2H expression level was increased in HCC tissues compared with the paratumoral liver tissues. SNF2H promotes the cell proliferation and colony formation ability of HCC cells in vitro. SNF2H The lentivirus plasmid-mediated SNF2H expression vectors pWPI.1-Flag-SNF2H, pLKO.1-shSNF2H#1 and pLKO.1-shSNF2H#2 were co-transfected with the helper plasmids pMD2.G and psPAX2 into HEK293T cell to package recombinant lentivirus. In total, 24 h subsequent to cell transfection, medium was replaced with fresh DMEM medium to continue cell culture. After 48 h, the lentivirus supernatants from HEK293T cells were used for the infection of BEL-7402 and Huh7 cells using Lipofectamine 2000 (Thermo Fisher Scientific, Inc.).
Western blot analysis. Total tissue and cell proteins were obtained using radioimmunoprecipitation assay buffer lysis buffer with proteinase inhibitors (protease inhibitor cocktail; Sigma-Aldrich, St. Louis, MO, USA). Equivalent amounts of proteins (30 µg) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes (Invitrogen; Thermo Fisher Scientific, Inc.). Subsequent to blocking with 5% skimmed milk for 30 min, the membranes were incubated with a rabbit polyclonal anti-SNF2H primary antibody (dilution, 1:500; catalog no., ab3749; Abcam, Cambridge, MA, USA) at 4˚C overnight. A goat anti-rabbit IgG horseradish peroxidase-conjugated secondary antibody (dilution, 1:3,000; catalog no., 7074; Cell Signaling Technology, Inc., Danvers, MA, USA) was used for the subsequent incubation at room temperature for 1 h. In addition, a mouse monoclonal β-actin horseradish peroxidase-conjugated antibody (dilution, 1:5,000; catalog no., ab20272; Abcam) was used as a loading control. The expression of SNF2H was detected on X-ray film using the ECL detection system (Pierce; Thermo Fisher Scientific, Inc.).
RNA isolation and reverse transcription-quantitative PCR (RT-qPCR).
Total RNA of the sample was extracted using TRIzol reagent (Thermo Fisher Scientific, Inc.), and RT was performed using the PrimeScript RT kit (Takara, Otsu, Japan). For the RT-qPCR assay, aliquots of cDNA were amplified using SYBR Premix Ex Taq (Takara). PCR reactions were performed on MXP3000 (Stratagene, La Jolla, CA, USA). The primer sequences were as follows: SFN2H forward, CCT TTG AAG ATG AAA CCA GGG CGC and reverse, CTG TTA ATA GCT CTT CAT CCT CCTC; and β-actin forward, TCC CTG GAG AAG AGC TACG and reverse, GTA GTT TCG TGG ATG CCACA.
Cell proliferation. Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies, Inc., Kumamoto, Japan) to measure the cell proliferation. BEL-7402-Mock, BEL-7402-SNF2H, Huh7-scr, Huh7-shSNF2H#1 and Huh7-shSNF2H#2 cell lines were seeded into 96-well plates at a density of 2x10 3 cells/well with DMEM medium containing 10% FBS. At the indicated time points (24, 48, 72 or 96 h), the cell absorbance was detected at 450 nm using xMark Microplate Spectrophotometer (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The CCK-8 assay procedure was performed according to the manufacturer's instructions.
Colony formation assay. BEL-7402-Mock, BEL-7402-SNF2H, Huh7-scr, Huh7-shSNF2H#1 and Huh7-shSNF2H#2 cell lines were separately seeded into 6-well plates at a density of 3x10 2 cells/well using DMEM medium containing 10% FBS, and the cells were cultured at 37˚C in a 5% CO 2 atmosphere. After 10-14 days of culturing, the cells were washed with PBS and fixed using 10% formaldehyde for 30 min. Finally, the cells were stained with Giemsa stain for 60 min.
Statistical Analysis. Pearson's χ 2 test or Fisher's exact test were used to compare SNF2H expression levels between tissue samples and the Student's t-test was used for quantitative variables. P<0.05 was considered to indicate a statistically significant difference.
Results

SNF2H is highly expressed in HCC.
The expression of SNF2H was first assessed in HCC and paired paratumoral liver tissues. The SNF2H protein level was significantly increased by 1.7-fold in HCC tissues compared with the matched paratumoral liver tissues (P= 0.018; Fig. 1A ). To confirm these results, the expression of SNF2H in 30 HCC specimens and the paired paratumoral liver tissues was evaluated. It was found that the expression of SNF2H in HCC specimens was increased 1.9-fold compared with the paired paratumoral liver tissues (P<0.001; Fig. 1B) . Next, the expression of SNF2H in the normal liver cell and HCC SMCC-7721, BEL-7402, PLC, Huh7 and MHCC-97H cell lines was examined. Western blotting showed that the HCC Huh7 and MHCC97H cell lines had increased SNF2H expression compared with the normal liver L02 cell line (Fig. 1C) . It was also found that the mRNA level of SNF2H in the HCC SMCC-7721, BEL-7402, PLC, Huh7 and MHCC-97H cell lines was increased 2.5-fold, 1.7-fold, 6.34-fold, 7.72-fold and 7.09-fold, respectively, compared with the mRNA level in the L02 cell line (P=0.0018, P=0.0160, P=0.0025, P=0.0027 and P=0.0102, respectively; Fig. 1D ). Overall, these results indicate that the high expression of SNF2H may improve the development of HCC.
Overexpression of SNF2H improves HCC cell growth.
BEL-7402 and Huh7 cells were used as model HCC cell lines for the following investigations. Lentivirus-mediated overexpression of SNF2H in the BEL-7402 cells and knockdown of SNF2H expression of SNF2H in the Huh7 cells were used to evaluated the function of SNF2H in HCC cell growth. Overexpression of SNF2H in BEL-7402 cells and knockdown of the expression of SNF2H in the Huh7 cells were performed ( Fig. 2A) (Fig. 2B) . Overexpression of SNF2H also increased the number of BEL-7402 cell colonies by 1.6-fold (P<0.001) (Fig. 2C) . However, knockdown of SNF2H expression reduced the number of Huh7 cell colonies by 50 and 70%, respectively (shSNF2H#1 vs. SCR, P=0.006; shSNF2H#2 vs. SCR, P<0.001) (Fig. 2C) . These results indicate that SNF2H improves HCC cell growth.
SNF2H promotes the protein levels of β-catenin and enhances its nuclear accumulation. The Wnt/β-catenin pathway is always aberrantly activated during the development of HCC, and the β-catenin expression level is often increased in HCC (3) (4) (5) 18, 19) . Therefore, the present study investigated whether SNF2H enhances β-catenin expression to promote tumor growth. It was found that the β-catenin protein level in BEL-7402 cells was upregulated 2.6-fold by the exogenous expression of SNF2H (P=0.0012; Fig. 3A ), but the β-catenin protein level was downregulated by 30% (shSNF2H#1 vs. SCR, P=0.008) and 70% (shSNF2H#2 vs. SCR, P=0.001) in Huh7 cells by SNF2H knockdown (Fig. 3B) . The increase in β-catenin protein levels may result in induced β-catenin transcription or improved β-catenin protein stability. The present study investigated whether SNF2H used this mechanism 
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to upregulate β-catenin protein levels. Subsequently, it was observed that neither SNF2H overexpression in BEL-7402 cells nor SNF2H knockdown in Huh7 cells resulted in different β-catenin mRNA levels compared with the control BEL-7402-MOCK (increase of 1.1-fold; P=0.158) and Huh7-Scr cells (shSNF2H#1 vs. SCR, decrease of 7%, P=0.62; shSNF2H#2 vs. SCR, increase of 8%, P=0.574) (Fig. 3C ). In addition, there were no differences in the cytoplasmic level of β-catenin. However, the nuclear level of β-catenin was markedly upregulated 2-fold in the SNF2H overexpression BEL-7402 cells compared with the control group (P=0.003) (Fig. 3D) . Knockdown of SNF2H did not change the cytoplasmic level of β-catenin, but the nuclear level of β-catenin was markedly downregulated by 20 and 70%, respectively, compared with the control group in the Huh7 cells (shSNF2H#1 vs. SCR, P=0.023; shSNF2H#2 vs. SCR, P=0.002) (Fig. 3E) . These results indicate that SNF2H may promote β-catenin protein levels and enhance the nuclear accumulation of β-catenin in HCC cells. Fig. 4A and B) . However, knockdown of the expression of SNF2H decreased the mRNA expression of cyclin D1 by 60% (shSNF2H#1 vs. SCR, P<0.001; shSNF2H#2 vs. SCR, P=0.0053) and c-MYC by 50% (shSNF2H#1 vs. SCR, P=0.0037; shSNF2H#2 vs. SCR, P<0.001) and also decreased protein levels in Huh7 cells compared with the control group ( Fig. 4A and B) . It was investigated whether SNF2H could activate the LEF luciferase reporter that is always used as indicator of the level of Wnt/β-catenin signaling pathway activity. Indeed, exogenous expression of SNF2H in HEK-293T cells could enhance the LEF luciferase reporter activity by 3.0-fold compared with the control group (P<0.001) (Fig. 4C) . Next, it was investigated whether SNF2H could also activate the LEF luciferase reporter activity in the HCC cells. Overexpression of SNF2H in BEL-7402 cells enhanced LEF luciferase reporter activity by 2.0-fold compared with the control group (P=0.0031) (Fig. 4D) . However, knockdown of SNF2H expression in Huh7 cells decreased LEF luciferase reporter activity by 50% (shSNF2H#1 vs. SCR, P=0.0166) and 60% (shSNF2H#2 vs. SCR, P=0.0018) compared with the control group (Fig. 4E) . These results indicate that SNF2H activates the Wnt/β-catenin signaling pathway to promote HCC cell growth.
SNF2H activates the
Discussion
HCC is the fifth most common cancer and the third most common cause of cancer-associated mortality worldwide. The incidence and mortality of HCC has been increasing rapidly worldwide in previous decades. China alone accounts for >50% of cases of HCC worldwide (20, 21) . Due to the poor prognosis of HCC patients, the molecular mechanism of HCC development urgently requires clarification. Although numerous genes associated with the development of HCC have been confirmed (22) (23) (24) (25) (26) , the mechanism of HCC development has not been well elucidated. In the present study, the expression of SNF2H in HCC specimens and the paired paratumoral liver tissues was assessed. It was found that the expression of SNF2H in HCC specimens was increased compared with the paired paratumoral liver tissues. The present findings suggest that SNF2H may be a novel intervention target for the treatment of HCC. The extremely poor prognosis of HCC is mainly due to tumor growth and vascular invasion (27) (28) (29) (30) . The molecular mechanism of HCC cell growth is not well known. Therefore, a thorough knowledge of the molecular mechanisms of 
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HCC cell growth is extremely important for the therapeutics for HCC patients. The present results showed that SNF2H plays a vital role in promoting HCC cell growth and colony formation ability, indicating that SNF2H is a vital factor for the development of HCC. The Wnt/β-catenin signaling pathway is aberrantly activated during the development of HCC (3) (4) (5) . When binding with Wnt ligands, the destruction complex, which includes adenomatous polyposis coli protein, casein kinase 1, Axin and glycogen synthase kinase 3, may not induce the degradation of β-catenin. Further, stabilized β-catenin may induce the expression of Wnt/β-catenin target genes by interacting with TCF/LEF transcription factors. Previous data show that certain Wnt target genes, such as cyclin D1 and c-MYC, regulate tumor cell growth (6, 31) . However, the association between SNF2H and the Wnt/β-catenin pathway in HCC remains unknown. In the present study, SNF2H was shown to activate the Wnt/β-catenin pathway in HCC cells by upregulating β-catenin protein levels and enhancing β-catenin nuclear translocation. The mechanism for SNF2H-mediated upregulation of the expression of β-catenin requires elucidation. Neither SNF2H-overexpression BEL-7402 cells nor SNF2H-knockdown Huh7 cells regulated β-catenin mRNA levels. Thus, it is possible that SNF2H may interfere with the degradation machinery of β-catenin. The mechanism of SNF2H enhancement of the nuclear translocation of β-catenin is a vital focus for additional investigation, which may indicate a novel target for the treatment of HCC patients.
SNF2H plays an important role in cell growth and viability (32, 33) . Stopka et al (13) reported that knockout of SNF2H reduced cell proliferation by the inhibition of mitosis. The present results showed that SNF2H also promotes cell proliferation in HCC. The role of SNF2H in carcinogenesis is well established. Mohamed et al (12) reported that SNF2H showed higher expression in prostatic neoplasia compared with benign prostatic hyperphasia. The results of this study suggest that SNF2H is important in prostate carcinogenesis (12) . Previously, another study observed increased expression of SNF2H in gastric cancer samples compared with normal mucosa (16) . However, no study has reported an association between SNF2H and HCC. The present study demonstrated that SNF2H expression was markedly upregulated in HCC tissues compared with the paired paratumoral liver tissues. The present results indicate that SNF2H may be a promising therapeutic target strategy for HCC patients.
